A Milestone in Vitiligo: Clinical Efficacy and Long-Term Repigmentation Trends

In ‘A Milestone in Vitiligo: Clinical Efficacy and Long-Term Repigmentation Trends,’ the expert dermatologist examined the following critical questions:

Why have conventional therapies for vitiligo often been considered insufficient for long-term disease control?

What was the study background and what improvements in repigmentation were observed after 52 weeks and 104 weeks of treatment with ruxolitinib cream? Why are these clinically relevant?

Led by the moderator, the panelists discussed how Janus kinase (JAK) inhibitors provide a dual advantage by targeting the Th1 arm of the immune system and stimulating melanocyte repigmentation more effectively than traditional steroids. David Rosmarin reviewed data from the TRu-V1 and TRu-V2 phase 3 programs, noting that while 30% of patients achieved 75% facial repigmentation at 24 weeks, that number rose to 50% at one year, with continued improvement through 104 weeks.

Throughout the conversation, the experts provided a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

Our next episode, ‘The Future Landscape: Topical vs. Systemic JAK Inhibitors in Vitiligo,’ further explores vitiligo, highlighting the emerging role of systemic therapies and the clinical nuances of selecting between topical and oral JAK inhibitors.